These results indicate that promoting glymphatic clearance of macromolecular metabolic proteins including Aβ, Tau, and apoE may counteract pathological cascades of AD in multiple aspects, potentially delaying the onset and development of the disease. The gene discussed is MAPT; the disease is Alzheimer disease.